康沣生物科技（上海）股份有限公司（股票名称：康沣生物-B，股票代码：06922）于2026年7月2日公布了截至2026年6月30日的股份变动月报表，显示公司在报告期内股本状况保持稳定。
根据公告披露，截至本月末，康沣生物-B注册股本总额为244,705,000股，包含149,033,579股于香港联合交易所有限公司上市流通的H股及95,671,421股非上市股份，面值均为人民币1元。本月未发生新增发行、回购或注销股份及库藏股份的变动，已发行股本总数与上月持平。
公告未提及任何股份期权、股权激励计划或可换股票据等相关变动信息。根据本次月报，公司现有股本结构持续稳定，公共持股量符合交易所相关规定，公司承诺继续遵守香港联交所《上市规则》和其他相关法律法规的要求。
本次公告由公司董事朱军代表签署并递交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.